Abstract
Introduction: leprosy remains a major public health problem in Brazil, particularly due to delayed diagnosis and associated physical disabilities. Grade 2 disability is a marker of disease severity and reflects failures in early detection. Objective: to confirm grade 2 disability assigned at the time of leprosy diagnosis and to analyze the epidemiological profile of patients in the state of Goiás, Brazil. Methods: this was an observational and descriptive study based on secondary data from the Health Surveillance Superintendence of Goiás, covering the years 2023 and 2024. Patients notified as having grade 2 disability at diagnosis were included. Data were obtained from the Notifiable Diseases Information System, Simplified Neurological Assessment forms, and the Grade 2 Disability Investigation System. Regional Health Departments submitted complementary documentation and photographs of hands, feet, and eyes, which were evaluated by specialists to confirm disability grading. Results: in 2023, 34.5% of cases initially classified as Grade 2 disability were not confirmed after expert review; in 2024, this proportion was 30.0%. Among confirmed cases, there was a predominance of low educational level, male sex, and multibacillary operational classification. Conclusion: the reassessment of grade 2 disability revealed inconsistencies in initial classification, indicating weaknesses in neurological evaluation. Accurate identification of disabilities is essential to improve epidemiological indicators, guide public health policies, and reduce the social and economic burden of leprosy.
References
1. Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase. Brasília: Ministério da Saúde; 2022.
2. Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Doenças Crônicas e Infecções Sexualmente Transmissíveis. Boletim Epidemiológico de Hanseníase 2025. Brasília: Ministério da Saúde; 2025.
3. Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Diretrizes para vigilância, atenção e eliminação da hanseníase como problema de saúde pública: manual técnico-operacional [Internet]. Brasília (DF): Ministério da Saúde; 2016 [cited 2025 Jan 20]. 58 p. Available from: https://biblioteca.cofen.gov.br/wp-content/uploads/2022/01/diretrizes-vigilancia-atencaoeliminacao-hanseniase.pdf.
4. World Health Organization. Global leprosy (Hansen disease) update, 2024: beyond zero cases – what elimination of leprosy really means. Wkly. Epidemiol. Rec. 2025[cited 2025 Feb 4];100(37):365-384. Available from: https://iris.who.int/handle/10665/382656.
5. Organização Mundial de Saúde. Estratégia Global de Hanseníase de 2021-2030 “Rumo a zero hanseníase”. Nova Delhi: Organização Mundial de Saúde; 2021.
6. Rathod DG, Jagati A, Chowdhary P. Disabilities in leprosy: an open retrospective analysis of institutional records. An Bras Dermatol. 2019;94(1):52-6. doi: https://doi.org/10.1016/j.abd.2019.07.001.
7. Moreira RJO, Bezerra JM, Santos FS, Pascoal LM, Santos LH, Santos Neto M. Clinical-epidemiological characteristics and temporal trend of new cases of grade 2 disability leprosy in the state of Maranhão, Brazil, 2011-2020. Epidemiol Serv Saúde. 2023;32(2):e2022435. doi: https://doi.org/10.1590/S2237-96222023000200026.
8. Véras GCB, Soares MJGO, Silva LHD, Moraes RMD. Perfil epidemiológico e distribuição espacial dos casos de hanseníase na Paraíba. Cad Saúde Colet. 2023;31(2):e31020488. doi: https://doi.org/10.1590/1414-462X202331020488.
9. Matos TS, Souza CDF, Oliveira Fernandes TRM, Santos MB, Brito RJVC, Matos DUS, et al. Time trend and identification of risk areas for physical disability due to leprosy in Brazil: an ecological study, 2001-2022. BMC Infect Dis. 2025;25(1):320. doi: https://doi.org/10.1186/s12879-025-10586-2.
10. Raposo MT, Reis MC, Caminha AVQ, Heukelbach J, Parker LA, Pastor-Valero M, et al. Grade 2 disabilities in leprosy patients from Brazil: need for follow-up after completion of multidrug therapy. PLoS Negl Trop Dis. 2018;12(7):e0006645. doi: https://doi.org/10.1371/journal.pntd.0006645.
11. Sanchez MN, Nery JS, Pescarini JM, Mendes AA, Ichihara MY, Teixeira CSS, et al. Physical disabilities caused by leprosy in 100 million cohort in Brazil. BMC Infect Dis. 2021;21(1):290. doi: https://doi.org/10.1186/s12879-021-05846-w.
12. Opromolla DVA. Atlas de hanseníase. Bauru: Instituto Lauro de Souza Lima; 2000.
13. Alliance Against Leprosy Institute. Cartilha de Direitos das Pessoas Atingidas pela Hanseníase. Curitiba, 2023. [cited 2024 Ago. 26]. Available from: https://aal.org.br/wp-content/uploads/2023/02/cartilha-MORHANguia-direitos-das-pessoas-atingidas-pela-hanseniase.pdf.
14. Teixeira RM. Direitos e garantias da pessoa atingida pela hanseníase. São Paulo: Editora Dialética; 2021. 129 p.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Carolina Zamboti Rodrigues Silva, Guilherme Holanda Bezerra, Maria Isabel Porto da Silva, Ana Lúcia Osório Maroccolo de Sousa